Equity Insider News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, April 29,
2025 /PRNewswire/ -- Across the western
healthcare landscape, artificial intelligence (AI) is being
increasingly adopted to simplify authorizations and cut through
layers of bureaucratic inefficiency. Rather than replacing
physicians — a scenario some tech leaders like Bill Gates have speculated about — the goal is
to enhance the capabilities of healthcare professionals. Momentum
in this space is being driven by recent initiatives from companies
like Avant Technologies, Inc. (OTCQB: AVAI), Koninklijke
Philips N.V. (NYSE: PHG), HEALWELL AI Inc. (TSX: AIDX)
(OTCQX: HWAIF), RadNet, Inc. (NASDAQ: RDNT), and iCad,
Inc. (NASDAQ: ICAD).
The article continued: Barclays analysts
forecast that the AI healthcare market will expand at a robust 30%
CAGR through 2030, as investment from hospitals, insurers, and
pharmaceutical giants continues to climb. A recent Deloitte
study further notes that 71% of healthcare executives expect
profitability to rise this year, in large part due to the growing
integration of AI technologies into clinical operations.
Avant Technologies and Ainnova Request Pre-Submission Meeting
with US FDA for VisionAI Platform Technology
Avant Technologies, Inc. (OTCQB: AVAI), an emerging
leader in AI-driven healthcare innovation, and its JV partner,
Ainnova Tech, Inc., (Ainnova), a leading healthcare
technology company focused on revolutionizing early disease
detection using artificial intelligence (AI), today announced that
The Center for Devices and Radiological Health of the U.S. Food
and Drug Administration (FDA) has received the company's
submission package requesting a pre-submission meeting with the
FDA for its VisionAI platform technology and is now under
review.
Ainnova is requesting a pre-submission meeting with the
FDA's review team to discuss any questions and/or concerns
about its proposed formal submission, including seeking advice to
finalize the protocol and obtain agency guidance for a clinical
trial of its VisionAI platform in the early detection of diabetic
retinopathy. A pre-submission meeting allows companies to clarify
regulatory requirements, get feedback on their plans, and
potentially avoid delays or issues during the formal review
process.
The clinical studies will aim to support an FDA 510(k)
submission to obtain clearance from the regulatory agency to market
its technology in the U.S.
Ai-nova Acquisition Corp. (AAC), the company formed by
the partnership between Avant and Ainnova to advance
and commercialize Ainnova's technology portfolio, including
its VisionAI platform and its versatile retinal cameras, has
worldwide licensing rights for this portfolio. The licensing rights
include the U.S., where the FDA regulates drug and medical device
development, so the success of Ainnova's interactions with
the FDA are paramount to marketing the technology portfolio
in the United States.
"This milestone reflects our two-tiered strategy, rapid
deployment in low-regulation markets where VisionAI operates as a
screening tool, and simultaneous progress toward FDA
clearance for the U.S. market," said Vinicio Vargas, CEO at Ainnova and a
member of AAC's Board of Directors. "Entering the U.S. will
unlock significant commercial potential, and early engagement with
regulators ensures we do so with speed, credibility, and a
validated product."
For medical device applicants like Ainnova, the FDA's
pre-submission program is useful to determine a clear regulatory
pathway for the successful launch of the device, including the
number of patients and the number of clinics that will be needed to
generate the necessary clinical data for the FDA to make an
informed decision on Ainnova's VisionAI platform.
For Avant, the pre-submission meeting will help define a
precise budget for the strategic partnership's entire FDA
process.
This follows Ainnova's recent strategic alignment with
Apollo Hospitals in Southeast
Asia, where the Vision AI platform has been cleared for
commercial deployment in Brazil,
and clinical pilots are being prepared across the Americas.
Avant and Ainnova have identified Brazil and the
United States as key strategic markets. Ainnova is
currently addressing regulatory pathways in Brazil with the support of its MDSAP
certification to meet ANVISA requirements, paving the way
for rapid market entry.
Ainnova is being guided by global CRO Fortrea
ahead of the important pre-submission meeting with the FDA.
The goal is to seek 510(k) clearance for Vision AI in detecting
diabetic retinopathy, a gateway to broader use across multiple
chronic disease categories.
Between FDA progress, high-profile alliances, and a
growing international presence, Avant Technologies continues
to carve out a niche in the convergence of AI, diagnostics, and
preventative care. Investors looking for small-cap exposure to the
healthcare AI revolution may want to keep AVAI on the radar
as these developments unfold.
CONTINUED... Read this and more news for Avant
Technologies at:
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-
need-to-know/
Philips N.V. (NYSE: PHG) recently announced an expanded
partnership with Ibex Medical Analytics to enhance its
AI-enabled digital pathology workflows. Their integrated solution
helps pathology labs detect cancers more quickly and accurately
while boosting productivity by up to 37%.
"Pathology provides key information for a precise diagnosis,"
said Sam Terese, President & CEO
of Alverno Laboratories. "The Philips and Ibex
solutions are especially beneficial to the diagnosis of cancer
cases because they aid our pathologists in making an accurate and
quick diagnosis. These integrated pathology solutions help us
provide the highest possible quality result that any lab can
deliver, getting answers back to our clinicians quickly and saving
patients sleepless nights, even on complex cases."
The new PIPS 6.0 system includes cloud archiving, better AI
integration, and optimized case management tools. These
improvements are designed to ease the growing workload on
pathologists and improve patient outcomes worldwide.
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) recently
completed its acquisition of Orion Health, significantly
expanding its global footprint in healthcare data interoperability
and AI-driven solutions. The deal brought access to a large base of
public sector clients and 150 million patient records worldwide,
strengthening HEALWELL's platform for actionable healthcare
insights.
"The acquisition of Orion Health represents a
transformative milestone for the Company, bringing large enterprise
customers, recurring revenues, strong operating margins and free
cashflow conversion to HEALWELL while providing a
significant new channel for the distribution of our best-in-class
AI products," said Dr. Alexander
Dobranowski, CEO of HEALWELL. "In addition, the
acquisition strengthens our position in the public sector, enabling
us to deepen our reach with government partners, thanks to Orion
Health's strong, long-standing relationships. With the added
synergies from WELL Health, we are poised to transform
healthcare through AI and data-driven innovation."
RadNet, Inc. (NASDAQ: RDNT) recently announced plans to
acquire iCad, Inc. (NASDAQ: ICAD), aiming to strengthen its
leadership in AI-powered breast cancer detection and diagnosis.
"With over 1,500 healthcare provider locations, facilitating
over 8 million annual mammograms in 50 countries, iCAD's
installed base and strong sales, engineering and marketing
capabilities will provide us with immediate broad and valuable
customer relationships and commercialization capabilities that can
accelerate our existing DeepHealth objectives," said Dr.
Howard Berger, President and CEO of
RadNet. "This business combination is expected to accelerate
our global leadership and commitment to AI-powered breast cancer
screening, and positions us to further advance population
health."
The deal will add iCAD's global network of over 1,500
healthcare locations to RadNet's DeepHealth platform,
expanding access to advanced screening technologies. The companies
believe the combination will speed up innovation, improve early
cancer detection, and enhance patient outcomes worldwide.
Source:
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-
need-to-know/
CONTACT:
Equity Insider
info@equity-insider.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
Equity Insider is a wholly-owned subsidiary of Market IQ Media
Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies
Inc. advertising and digital media from the company directly. There
may be 3rd parties who may have shares Avant Technologies Inc., and
may liquidate their shares which could have a negative effect on
the price of the stock. This compensation constitutes a conflict of
interest as to our ability to remain objective in our communication
regarding the profiled company. Because of this conflict,
individuals are strongly encouraged to not use this publication as
the basis for any investment decision. The owner/operator of MIQ
own shares of Avant Technologies Inc. which were purchased in the
open market. MIQ reserves the right to buy and sell, and will buy
and sell shares of Avant Technologies Inc. at any time thereafter
without any further notice. We also expect further compensation as
an ongoing digital media effort to increase visibility for the
company, no further notice will be given, but let this disclaimer
serve as notice that all material disseminated by MIQ has been
approved by the above mentioned company; this is a paid
advertisement, and we own shares of the mentioned company that we
will sell, and we also reserve the right to buy shares of the
company in the open market, or through other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between any predictions and actual results.
Always consult a licensed investment professional before making any
investment decision. Be extremely careful, investing in securities
carries a high degree of risk; you may likely lose some or all of
the investment.
Logo:
https://mma.prnewswire.com/media/2644233/5292806/Equity_Insider_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/clinical-ai-platforms-expand-globally-amid-regulatory-and-market-tailwinds-302441476.html
